Piper Jaffray Companies set a $116.00 target price on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a research report sent to investors on Wednesday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other research firms also recently commented on ALNY. Vetr downgraded shares of Alnylam Pharmaceuticals from a strong-buy rating to a buy rating and set a $71.50 price target on the stock. in a research note on Monday, May 15th. Chardan Capital decreased their price target on shares of Alnylam Pharmaceuticals from $110.00 to $95.00 and set a buy rating on the stock in a research note on Monday, May 15th. Ladenburg Thalmann Financial Services set a $80.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, May 17th. Credit Suisse Group AG downgraded shares of Alnylam Pharmaceuticals to a hold rating and set a $50.00 target price on the stock. in a research note on Monday, March 20th. Finally, BMO Capital Markets initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, April 17th. They issued an outperform rating and a $73.00 target price on the stock. Seven analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $70.87.

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up 0.26% during midday trading on Wednesday, reaching $70.15. 588,467 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $56.31 and a 200-day moving average of $48.00. Alnylam Pharmaceuticals has a 12 month low of $31.38 and a 12 month high of $80.11. The stock’s market cap is $6.05 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Friday, May 5th. The biopharmaceutical company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.22) by $0.03. The business had revenue of $19 million for the quarter, compared to analysts’ expectations of $22.91 million. Alnylam Pharmaceuticals had a negative return on equity of 37.25% and a negative net margin of 869.63%. The company’s revenue was up 160.3% compared to the same quarter last year. During the same period last year, the business posted ($1.21) earnings per share. On average, equities research analysts predict that Alnylam Pharmaceuticals will post ($5.35) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This report was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/05/25/alnylam-pharmaceuticals-inc-alny-given-a-116-00-price-target-by-piper-jaffray-companies-analysts.html.

In other news, VP Michael Mason sold 9,375 shares of the company’s stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total transaction of $656,250.00. Following the completion of the sale, the vice president now owns 5,625 shares of the company’s stock, valued at approximately $393,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Akshay Vaishnaw sold 43,750 shares of the company’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $65.00, for a total transaction of $2,843,750.00. Following the sale, the senior vice president now directly owns 43,047 shares of the company’s stock, valued at approximately $2,798,055. The disclosure for this sale can be found here. 4.00% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the stock. Dodge & Cox acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $344,633,000. BlackRock Inc. raised its stake in Alnylam Pharmaceuticals by 34,755.2% in the first quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock valued at $243,242,000 after buying an additional 4,732,617 shares during the last quarter. Perceptive Advisors LLC raised its stake in Alnylam Pharmaceuticals by 831.4% in the first quarter. Perceptive Advisors LLC now owns 1,103,475 shares of the biopharmaceutical company’s stock valued at $56,553,000 after buying an additional 985,000 shares during the last quarter. 12 West Capital Management LP acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $26,208,000. Finally, Norges Bank acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $24,885,000. 88.70% of the stock is owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

12 Month Chart for NASDAQ:ALNY

Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.